A short term study of the additive effect of timolol and brimonidine on intraocular pressure

Abstract

A short term study of A Topalkara the additive effect of timolol and brimonidine on intraocular pressure AbstractPurpose To evaluate the additive ocular hypotensive effect of the combination of brimonidine and timolol on intraocular pressure (IOP) reduction in patients with glaucoma. Methods This was a prospective, randomized, double-masked, crossover study in 20 patients with primary open angle glaucoma (POAG) on therapy receiving timolol maleate 0.5% twice daily, with IOP greater than or equal to 22 mmHg in one eye. The treatment period was 3 weeks and during this period timolol + brimonidine or timolol + placebo were applied topically twice daily and IOP, blood pressure, heart rate and pupil size were measured. Results Combined therapy (timolol + brimonidine) had clinically significant IOPlowering effect during the treatment period (P Ͻ 0.01). The mean diurnal IOP was significantly reduced by an average of 5.1-5.9 mmHg (21.2-24.5%) compared with baseline value. The timolol + placebo combination had no clinically significant IOP-lowering effect (P Ͼ 0.05). No clinically significant side effects were observed during the treatment of both groups. Conclusions This study showed that the combination of topically applied brimonidine and timolol cause a marked and sustained IOP reduction.

Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma

“…[3] In another short-term 3-week study found that the mean IOP was significantly reduced by an average of 5.44 ± 1.98 mmHg compared with baseline value with the use of the fixed combination. [4] Thus the results of our study are in congruence with these studies further supporting the additive IOP lowering effect of the brimonidine-timolol fixed combination. Data from the Early Manifest Glaucoma Trial have shown that even 1 mm Hg of additional IOP lowering reduces the risk of glaucoma progression by 10%.…”

A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension

“…[4][5][6][7] Approved for use in 1977, timolol given once or twice daily lowers IOP in POAG and OH by reducing the production of aqueous humour. [8][9][10] Latanoprost, the first prostaglandin F 2a analogue to be commercially available in Europe and the US, has been shown to lower IOP more effectively than timolol when administered once daily.…”

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure

“…Another similar study (Arici et al 2002) evaluated the effect of adjunctive brimonidine in timolol-treated subjects over a longer time period of 3 weeks. IOP reduction of 5.1 mmHg (21.2%), 5.9 mmHg (24.5%), and 5.7 mmHg (23.6%) at weeks 1, 2, and 3 respectively was found.…”